Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 154 for “"factor VIII"”.
-
Molecular characterization of factor VIII gene
… BLEEDING DISORDER CAUSED BY MUTATIONS IN THE FACTOR VIII GENE. IN THIS STUDY, 55 UNRELATED HAEMOPHILIA A PATIENTS, PREVIOUSLY SCREENED AND FOUND NEGATIVE FOR THE COMMON INTRON 22 INVERSION MUTATION, WERE CHARACTERIZED BY DIRECT PCR-BASED SEQUENCING OF THE PROMOTER, 26 EXONS AND THE FLANKING …
-
Endothelial cell synthesis of Factor VIII
Factor VIII (FVIII) is an essential blood-clotting protein and mutations in the FVIII gene are the cause of hemophilia A, a severe inherited bleeding disorder. FVIII synthesis has been observed in discreet endothelial sub-populations including liver sinusoidal endothelial cells and in selected …
-
The role of factor VIII in blood coagulation
<p>Factor VIII, a component of the intrinsic pathway of blood coagulation, has yet to be purified to homogeneity. It appears that, <em>in vivo</em>, the factor VIII coagulant protein is closely associated with one or more other proteins (factor VHI-related antigen and platelet aggregating factor). …
-
Chemical modification and immunological studies on recombinant factor VIII
Factor VIII (FVIII) is a high molecular weight glycoprotein which is deficient or functionally defective in Haemophilia A. It circulates in normal plasma as part of a complex with von Willebrand factor (vWF). In the absence of vWF, FVIII is highly unstable. The effects of chemical modifiers on …
-
Early mechanisms of factor VIII immunity in hemophilia A
… response to the therapeutically-administered factor VIII (FVIII). A better understanding of initiating events leading to FVIII immunity may highlight alternative treatment interventions. We have explored this synapse at the level of the FVIII protein, the cellular interactions, and the …
-
Studies on the procurement of blood coagulation factor VIII
Coagulation factor VIII is needed for the treatment of patients with haemophilia. Requirements for factor VIII are important in determining the numbers of blood donations to be collected in Scotland. The final yield of factor VIII:C in products prepared from blood plasma, when prepared either in …
-
Purification of bovine blood clotting Factor VIII (antihemophilic globulin)
Thesis (Ph. D.)--Michigan State University. Department of Physiology, 1966
-
Hepatitis A virus in relation to contamination of factor VIII
… hemophiliacs receiving solvent detergent treated factor VIII in Europe and the USA have recently caused concern to blood product manufacturers and control agencies. In this study, the use of terminal dry heat treatment to inactivate HAV (strains HM175A.2 and HM175/18f) in spiked factor VIII was …
-
The Thrombogenic Influences of Factor VIII and von Willebrand Factor
von Willebrand factor (VWF) and factor VIII (FVIII) circulate in the blood as a non-covalent complex. VWF plays an important role in primary hemostasis through its interactions with components of the extracellular matrix and platelet glycoproteins, as well as through its stabilization of FVIII. …
-
Tolerance Induction and The Immunobiology of Factor VIII in Hemophilia A
The development of inhibitory antibodies to the factor VIII (FVIII) protein is the greatest complication in the management of hemophilia A patients. These antibodies, which form in approximately 25% of patients, neutralize the procoagulant activity of FVIII. There are limited treatment options to …
-
SUBLINGUAL IMMUNOTHERAPY INDUCES TOLERANCE TO FACTOR VIII IN HEMOPHILIA A MICE
… or decreased amount of functional coagulation Factor VIII (FVIII) in the blood. The clinical manifestations of HA include uncontrolled bleeding events, spontaneous muscle bleeding, and joint bleeding leading to the painful swelling of joints. There is currently no cure for HA, the treatment for …
-
Novel Methods of Factor VIII Tolerance Induction in Hemophilia A Mouse Models
The most serious complication of factor VIII (FVIII) replacement therapy in hemophilia A (HA) patients remains the development of anti-FVIII antibodies (inhibitors). At this time, there are no methods to prevent inhibitor development and immune tolerance induction (ITI) therapy is difficult and …
-
Characterization of factor VIII inhibitor by-passing activity of factor IX concentrates
Thesis (M.S.)--Michigan State University. Department of Pathology, 1983
-
Generation of Long-Acting Coagulation Factor VIII for the Treatment of Haemophilia A
… resulting from dysregulation of clotting factor VIII (FVIII) during haemostasis. Predominant mode of treatment is by replacement therapy with recombinant FVIII (rFVIII) on demand or as a prophylaxis (Berntorp et al., 2003, Gouider et al., 2015). While there are a number of rFVIII products …
-
Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII
… crucial member of the coagulation cascade, the cofactor Factor VIII, were investigated using fluorescence spectroscopy, interference immunoassays, commercially produced Factor VIII activity kits, and equilibrium dialysis. The results suggest not only that the peptides interact with the coagulation …
-
Characterization of the Recombinant Human Factor VIII Expressed in the Milk of Transgenic Swine
Factor VIII is a protein which has therapeutic applications for the treatment of Hemophilia A. Its deficiency, either qualitative or quantitative, results in Hemophilia A, a disorder affecting approximately 1 in 10,000 males. Currently, FVIII replacement therapy uses FVIII derived from plasma or …
-
Low Zone Tolerance Induction to Coagulation Factor VIII in a Hemophilia A Mouse Model
… caused by a decrease/absence of coagulation Factor VIII (FVIII) in circulation. Management involves administration of FVIII to prevent bleeding episodes. The most serious complication of this replacement therapy is the development of inhibitory anti-FVIII antibodies which neutralize the …
Page 1 of 8